Molecular Biomarkers and Histological Parameters Impact on Survival and Response to First- Line Systemic Therapy of Metastatic Colorectal Cancer Patients

por Rebersek, Martina, Mesti, Tanja, Boc, Marko, Ocvirk, Janja
Publicado 2019

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience

por Mesti, Tanja, Moltara, Maja Ebert, Boc, Marko, Rebersek, Martina, Ocvirk, Janja
Publicado 2015

Prevalence of BRAF, NRAS and c-KIT Mutations in Slovenian Patients with Advanced Melanoma

por Moltara, Maja Ebert, Novakovic, Srdjan, Boc, Marko, Bucic, Marina, Rebersek, Martina, Zadnik, Vesna, Ocvirk, Janja
Publicado 2018

Retrospective Analysis of Treatment-naive Slovenian Patients with Metastatic Melanoma Treated with Pembrolizumab – Real-world Experience

por Hribernik, Nezka, Boc, Marko, Ocvirk, Janja, Knez-Arbeiter, Jasna, Mesti, Tanja, Ignjatovic, Marija, Rebersek, Martina
Publicado 2020

Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer – a single institution retrospective analysis...

por Rebersek, Martina, Boc, Marko, Cerkovnik, Petra, Benedik, Jernej, Hlebanja, Zvezdana, Volk, Neva, Novakovic, Srdjan, Ocvirk, Janja
Publicado 2011

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience

por Ocvirk, Janja, Moltara, Maja Ebert, Mesti, Tanja, Boc, Marko, Rebersek, Martina, Volk, Neva, Benedik, Jernej, Hlebanja, Zvezdana
Publicado 2016